GRWR Correlates with the Metabolism of Tacrolimus after Pediatric Living Donor Liver Transplantation According to Donor CYP3A5 Polymorphism
Table 2
Baseline characteristics of recipients.
Variable
SS/NEX group ()
SS/EX group ()
LS/NEX group ()
LS/EX group ()
Age (month)
12.2 (5.7-71.5)
10.9 (5.7-63.4)
7.6 (5.1-22.2)
8.1 (4.8-53.6)
Gender
Boy
24 (60.0)
19 (50.0)
20 (41.7)
23 (47.9)
Girl
16 (40.0)
19 (50.0)
28 (58.3)
25 (52.1)
Weight (kg)
9.3 (5.9-28.0)
9.0 (6.0-18.0)
6.9 (5.1-12.0)
7.0 (5.3-10.5)
Height (cm)
70 (60-120)
70.5 (58-108)
65 (56-76)
65 (57-88)
PELD score
13 (-9-28)
16 (-10-29)
17 (-2-36)
19 (-9-37)
ABO blood group
A
16 (40.0)
8 (21.1)
11 (22.9)
10 (20.8)
B
9 (22.5)
12 (31.6)
13 (27.1)
13 (27.1)
O
9 (22.5)
16 (42.1)
19 (39.6)
19 (39.6)
AB
6 (15.0)
2 (5.3)
5 (10.4)
6 (12.5)
ABO compatibility
Identical
30 (75.0)
32 (84.2)
39 (81.3)
35 (72.9)
Compatible
9 (22.5)
4 (10.5)
8 (16.7)
12 (25.0)
Incompatible
1 (2.5)
2 (5.3)
1 (2.1)
1 (2.1)
Etiology
Biliary atresia
31 (77.5)
35 (92.1)
47 (97.9)
47 (97.9)
Cholestatic liver cirrhosis
0
1 (2.6)
0
0
PFIC
2 (5.0)
0
0
1 (2.1)
Cryptogenic liver cirrhosis
0
1 (2.6)
0
0
Tyrosinemia
4 (10.0)
0
0
0
Abernethy syndrome
1 (2.5)
0
0
0
Glycogen storage disease
1 (2.5)
0
0
0
Caroli disease
0
0
1 (2.1)
0
Alagille syndrome
0
1 (2.6)
0
0
Niemann-Pick disease
1 (2.5)
0
0
0
Kasai procedure
Yes
16 (40.0)
19 (50.0)
21 (43.8)
14 (29.2)
No
24 (60.0)
19(50.0)
27 (56.3)
34 (70.8)
Transplant stage
2009-2012
18 (45.0)
20 (52.6)
17 (35.4)
9 (18.8)
2013-2014
22 (55.0)
18 (47.4)
31 (64.6)
39 (81.3)
Note: Data are expressed as number (%) or median (range). GRWR: graft-to-recipient body weight ratio; PELD: pediatric end-stage liver disease; PFIC: progressive familial intrahepatic cholestasis.
